Shoeshine
|
Friday 14th November 2003 |
Text too small? |
The issues are old ones. First, the company didn't live up to the 2001 information memorandum ebitda (earnings before interest, tax, depreciation and amortisation) forecast of $18.3 million for the August 2002 year.
That's disappointing for everyone but in the context of a rocketing exchange rate, low beef prices for Tru-Test's customers and the Australian drought, it's scarcely surprising.
The Neuronz purchase has also aggravated some shareholders but, like the company's financial performance, that was known before last year's annual meeting, at which, apparently, no questions were asked.
The theory getting most traction is that someone is trying to unsettle shareholders and turn up the gas on Tru-Test's board and management to smooth the path of a takeover.
The natural candidate for the bidder is Skellmax Industries, whose largest shareholder, Axa Asia Pacific, has 5.67%.
It's a small country. Axa is also one of Tru-Test's shareholders.
No comments yet
HGH - Heartland 2026 Annual General Meeting
WHS provides FY27 first quarter trading update
AIA - successfully completes new A$300 million AMTN issue
November 13th Morning Report
SPK - Response to open letter regarding FY26 financial statements
HGH - Update on proposed TSB transaction target completion date
MFT - Mainfreight Half Year Financial Results 30 September 2026
MCY - Executive leadership team changes
November 12th Morning Report
GTK - FY26 Investor Briefing Details